Published in Arch Pathol Lab Med on April 01, 2006
Secretory breast carcinoma in a 6-year-old girl: mastectomy with sentinel lymph node dissection. Pediatr Surg Int (2015) 0.75
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol (2008) 3.09
Interpretative problems and preparative technique influence reliability of intraoperative parathyroid touch imprints. Arch Pathol Lab Med (2003) 2.02
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer (2007) 1.73
Primary osteosarcoma of the breast: report of 2 cases. Arch Pathol Lab Med (2007) 1.55
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol (2009) 1.51
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila) (2009) 1.47
Imaging features of micropapillary DCIS: correlation with clinical and histopathological findings. Acad Radiol (2011) 1.39
Pathological examination of sentinel lymph node in breast cancer: potential problems and possible solutions. Microsc Res Tech (2002) 1.38
Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol (2007) 1.33
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat (2007) 1.31
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med (2009) 1.29
Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol (2007) 1.29
Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer (2014) 1.24
Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res (2006) 1.21
Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol (2011) 1.14
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat (2011) 1.06
Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol (2004) 1.00
Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol (2012) 0.94
Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol (2014) 0.93
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer (2011) 0.92
Triple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol (2011) 0.89
Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol (2008) 0.89
Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat (2008) 0.88
Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature. APMIS (2012) 0.88
Preoperative diagnosis of clear cell "sugar" tumor of the lung by computed tomography-guided fine-needle biopsy and core-needle biopsy. Ann Diagn Pathol (2007) 0.86
Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol (2010) 0.86
Cytologic features of renal medullary carcinoma. Cancer (2005) 0.85
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol (2011) 0.83
Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology (2011) 0.83
Primary gastrointestinal stromal tumor of the esophagus in an HIV-positive patient. Ann Diagn Pathol (2005) 0.82
Megakaryocytes mimicking metastatic breast carcinoma. Arch Pathol Lab Med (2002) 0.82
Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web-based survey. Pathol Res Pract (2010) 0.81
Trastuzumab administration associated with change in HER2 status. Clin Breast Cancer (2008) 0.81
Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology (2012) 0.80
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat (2012) 0.80
Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol (2010) 0.78
The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol (2012) 0.78
Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation. Ann Surg (2017) 0.76
Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J (2010) 0.76
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Ann Diagn Pathol (2012) 0.76
Giant cell tumor of soft tissue arising in breast. Ann Diagn Pathol (2007) 0.75
Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow-up. Chin J Cancer (2014) 0.75
Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med (2010) 0.75
Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy. Radiology (2010) 0.75
Androgen Receptor (AR) Expression in Invasive Male Breast Carcinoma (MBC): An International Multi-Institutional Review of 168 Cases Emphasizing the Potential Use of AR as a Therapeutic Target. Appl Immunohistochem Mol Morphol (2017) 0.75
Androgen Receptor (AR) Expression in Invasive Male Breast Carcinoma (MBC): An International Multi-Institutional Review of 168 Cases Emphasizing the Potential Use of AR as a Therapeutic Target. Appl Immunohistochem Mol Morphol (2017) 0.75